Industry News
Pharmaceutical Industry News
With Ebvallo’s latest U.S….
With Ebvallo’s latest U.S. rejection, Atara Biotherapeutics and its partner Pierre Fabre Pharmaceuticals are accusing the FDA of pulling an about-face.
Cellares, the contract drugmaker…
Cellares, the contract drugmaker known for its cell therapy factory-in-a-box, will expand its operations to Europe after inking a long-term lease for space that will house manufacturing and offices in the Netherlands.
Already on track to achieve…
Already on track to achieve blockbuster status in its third full year on the market, Bristol Myers Squibb’s cardiomyopathy treatment Camzyos has scored in a trial that could pave the way for it to become
With $10 billion pledged to beef…
With $10 billion pledged to beef up its U.S. operations through 2035, AbbVie has already unveiled plans for a new drug ingredient plant in its home state of Illinois and an expansion of its bioresearch
Joel Habener, Whose Research Led to Weight-Loss Drugs, Dies at 88
His discovery of the protein fragment GLP-1 was crucial in the development of Ozempic, Wegovy and other blockbuster obesity and diabetes treatments.
Can A.I. Help Medical Research?
Sam Rodriques, the C.E.O. and co-founder of FutureHouse, discusses the bottlenecks around A.I. drug development, and how Kosmos – the company’s A.I. scientist – aims to solve some of these hurdles and accelerate medical discovery.
RTI Health Solutions leaders…
RTI Health Solutions leaders explain how patient voices are reshaping evidence generation, access and value communication
The LeonaBio rebrand comes from…
The LeonaBio rebrand comes from the name Leona, which means lioness and reflects the company's "commitment to leadership, resilience, and innovation," CEO Mark Litton, Ph.D., said.
Orca Bio has disclosed $250…
Orca Bio has disclosed $250 million in funding, flooding its balance sheet with cash to buoy preparations for the commercialization of a blood cancer cell therapy.
Add Johnson & Johnson to the…
Add Johnson & Johnson to the list of biopharma giants that have struck most-favored-nation (MFN) drug pricing deals with the Trump administration. The company also announced plans to build new manufacturing facilities in Pennsylvania and
Early launch numbers of Brinsupri…
Early launch numbers of Brinsupri are so strong that Insmed couldn’t wait for the J.P. Morgan Healthcare Conference to share them. The first-in-class inflammatory drug shattered Wall Street estimates in its first full quarter on
The next phase of Novartis’ $23…
The next phase of Novartis' $23 billion U.S. investment drive will center on a 35,000-square-foot radioligand therapy (RLT) facility in Winter Park, Florida. Joining established plants in Novartis’ American RLT network in Indiana, New Jersey
UCB, AbbVie and Legend Biotech are…
UCB, AbbVie and Legend Biotech are among the companies presenting at the JPM conference today. We'll keep you up to speed throughout the day in this tracker.
Today will feature presentations…
Today will feature presentations from Big Pharmas including GSK, AstraZeneca and Novo Nordisk, and Fierce's own event kicks off at the Hyatt Regency. Be sure to check in all day to stay on top of
After a flurry of Big Pharma deals…
After a flurry of Big Pharma deals in the first week of the new year, the life sciences industry is heading to San Francisco for the industry's biggest investor event of the year. Be sure
Trump Says He ‘Probably Should’ Take Obesity Drugs, but Has Not
President Trump has talked in the past about people he knows who have taken “the fat drug.”
In the past three weeks, a flurry…
In the past three weeks, a flurry of licensing deals with Chinese biotechs were announced featuring, AbbVie, AstraZeneca, Servier, Sanofi and Ipsen. Shionogi also beefed up its rare disease portfolio with a $2.5 billion deal
As evidence of tirzepatide’s…
As evidence of tirzepatide’s efficacy mounts across a range of cardiometabolic conditions, Eli Lilly has shown that taking the incretin medicine alongside another of its drugs, Taltz, could lead to better outcomes for patients living
In a saga that has spread over…
In a saga that has spread over seven years, the FDA has again rejected Vanda’s bid to expand the label for Hetlioz to treat jet lag disorder. The new rejection came three months after the
Shortly after floating a…
Shortly after floating a contingency plan for its asset, vilobelimab—which boasts an emergency use authorization for COVID-19 in the U.S.—Germany’s InflaRx is drafting bigger changes to its organization as it looks to cut costs and